TY - JOUR T1 - Phase I Study Evaluating the Combination of Afatinib with Carboplatin and Pemetrexed After First-line EGFR-TKIs JF - Anticancer Research JO - Anticancer Res SP - 4699 LP - 4704 DO - 10.21873/anticanres.12776 VL - 38 IS - 8 AU - SATOSHI WATANABE AU - OU YAMAGUCHI AU - AI MASUMOTO AU - YURI MAENO AU - YOSUKE KAWASHIMA AU - OSAMU ISHIMOTO AU - SHUNICHI SUGAWARA AU - HIROHISA YOSHIZAWA AU - TOSHIAKI KIKUCHI AU - TOSHIHIRO NUKIWA AU - KUNIHIKO KOBAYASHI Y1 - 2018/08/01 UR - http://ar.iiarjournals.org/content/38/8/4699.abstract N2 - Background/Aim: Promising reports have described the combination of first-generation epidermal growth factor receptor tyrosine-kinase inhibitors (EGFR-TKIs) with carboplatin plus pemetrexed or bevacizumab. However, no analysis of afatinib with platinum-doublet chemotherapies has been performed. Patients and Methods: We evaluated the safety and antitumor efficacy of afatinib combined with carboplatin and pemetrexed in EGFR-mutated non-small-cell lung cancer (NSCLC) patients who progressed during first-generation EGFR-TKIs. Results: Ten patients received 20 or 30 mg/day afatinib with carboplatin (area under the curve, 5) and pemetrexed (500 mg/m2). Dose-limiting toxicities included delay of afatinib ≥14 days, grade 3 diarrhea, grade 3 hypokalemia, grade 3 serum amylase increase and grade 4 thrombocytopenia. The recommended dose of afatinib was 20 mg/day in this combination therapy. Overall response rate was 30% and median progression-free survival was 13.7 months. Conclusion: This is the first study to investigate the combination of afatinib, carboplatin and pemetrexed. At the recommended dose, this combination was well tolerated and had a good clinical efficacy. ER -